BCDA BioCardia

BioCardia to Present at the LD Micro 500 Virtual Conference on September 1, 2020

BioCardia to Present at the LD Micro 500 Virtual Conference on September 1, 2020

SAN CARLOS, Calif., Aug. 26, 2020 (GLOBE NEWSWIRE) --  [Nasdaq: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies today announced that Peter Altman, Ph.D., Biocardia’s Chief Executive Officer will give a virtual corporate presentation at the LD Micro 500 taking place online on Tuesday, September 1, 2020 at 10:20 AM ET followed by a live question and answer session with registered investors and other conference attendees.

Webcast link:

In addition, Dr. Altman will be available for virtual one-on-one meetings beginning on September 1, 2020 and through September 4, 2020.  To schedule a meeting, please contact Eric Lahiji at .

About BioCardia

BioCardia, Inc., headquartered in San Carlos, California, is developing regenerative biologic therapies to treat cardiovascular disease. CardiAMP autologous and Neurokinin-1 Receptor Positive allogenic cell therapies are the Company’s biotherapeutic platforms in clinical development. The Company's products include the Helix Biotherapeutic Delivery System and its steerable guide and sheath catheter portfolio. BioCardia also partners with other biotherapeutic companies to provide its Helix system and clinical support for their programs studying therapies for the treatment of heart failure, chronic myocardial ischemia and acute myocardial infarction. For more information, visit .

Media Contact:

Michelle McAdam, Chronic Communications, Inc.



(310) 902-1274

Investor Contact:

David McClung, Chief Financial Officer



(650) 226-0120

EN
26/08/2020

Underlying

BCDABioCardia

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BioCardia

 PRESS RELEASE
Free
BCDA BIOCARDIA

BioCardia Files Request for Meeting With FDA to Discuss Accelerated Ap...

BioCardia Files Request for Meeting With FDA to Discuss Accelerated Approval Pathway for CardiAMP® System in Ischemic Heart Failure SUNNYVALE, Calif., April 02, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported submission to United States Food and Drug Administration (FDA) of the CardiAMP HF clinical study data and on its plans to meet with the FDA to discuss the accelerated approval pathway for the CardiAMP® System for ischemic chronic heart failure...

April 2, 2026 1 EN
 PRESS RELEASE
Free
BCDA BIOCARDIA

BioCardia Reports 2025 Business Highlights and Financial Results

BioCardia Reports 2025 Business Highlights and Financial Results SUNNYVALE, Calif., March 24, 2026 (GLOBE NEWSWIRE) --  [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for the year ended December 31, 2025 and filed its annual report on Form 10-K with the Securities and Exchange Commission. The Company will host a corporate update conference call today, on Tuesday, March 24, 2026, at 4:30 PM ET, in which it will discuss business highlights. Call details and dial-in are pr...

March 24, 2026 1 EN
 PRESS RELEASE
Free
BCDA BIOCARDIA

BioCardia to Host 2025 Financial Results and Corporate Update Conferen...

BioCardia to Host 2025 Financial Results and Corporate Update Conference Call on March 24, 2026 SUNNYVALE, Calif., March 19, 2026 (GLOBE NEWSWIRE) -- [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will provide a corporate update and report its financial results for the year ended December 31, 2025 by conference call on Tuesday, March 24, 2026 at 4:30 PM EDT. Following management’s formal remarks, there will be a question-and-answer session. Participants can register for the conference by...

March 19, 2026 1 EN
 PRESS RELEASE
Free
BCDA BIOCARDIA

BioCardia Announces Pre-Submission Approval Package for Helix Transend...

BioCardia Announces Pre-Submission Approval Package for Helix Transendocardial Delivery Catheter Accepted by FDA FDA Substantive Review and Meeting Scheduled for Early Q2 SUNNYVALE, Calif., March 17, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the FDA has accepted its pre-submission package for the approval of its Helix Transendocardial Delivery Catheter (“Helix”) intended for intramyocardial therapeutic and diagnostic agent delivery.    BioCar...

March 17, 2026 1 EN
 PRESS RELEASE
Free
BCDA BIOCARDIA

BioCardia Late Breaking Echocardiography Clinical Results from CardiAM...

BioCardia Late Breaking Echocardiography Clinical Results from CardiAMP HF Trial Presented at Technology and Heart Failure Therapeutics (THT) Echocardiography outcomes show treated patients having reduced negative remodeling of heart volumes   SUNNYVALE, Calif., March 03, 2026 (GLOBE NEWSWIRE) --  [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported late breaking echocardiography results from its Phase III clinical trial for ischemic heart failure of reduced ejection fraction (HFrEF), which affec...

March 3, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch